How should post‑traumatic restless‑legs syndrome be diagnosed and managed?

Post-Traumatic Restless Legs Syndrome: Diagnosis and Management

Diagnosis

Post-traumatic RLS in spinal cord injury (SCI) patients should be diagnosed using the same five essential criteria as primary RLS, but clinicians must actively distinguish it from post-traumatic spastic syndrome and neuropathic pain, which are common misdiagnoses in this population. 1, 2

Essential Diagnostic Criteria (All Must Be Met)

• An urge to move the legs, usually accompanied by uncomfortable and unpleasant sensations in the legs (and sometimes arms or other body parts in SCI patients) 1, 2
• The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity 1
• Symptoms are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues 1
• Symptoms occur or worsen in the evening or night compared to during the day 1
• The symptoms are not solely accounted for as primary to another medical or behavioral condition (e.g., myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort) 1

Critical Diagnostic Pitfall in SCI Patients

• Without proper differential diagnosis, infralesional involuntary movements and dysesthesia in SCI patients are frequently misattributed to post-traumatic spasticity or neuropathic pain, leading to years of ineffective treatment with antispasmodics and analgesics. 2
• A case series documented four men with chronic SCI suffering from refractory symptoms previously treated as spastic syndrome or neuropathic pain who responded excellently to dopamine agonist therapy when correctly diagnosed with RLS 2
• RLS symptoms can occur in both complete and incomplete SCI, affecting lower extremities and sometimes upper extremities 2

Laboratory Evaluation

• Check morning fasting serum ferritin and transferrin saturation after avoiding iron-containing supplements for at least 24 hours 3
• Supplement iron if ferritin ≤75 ng/mL or transferrin saturation <20% (RLS-specific thresholds, different from general population) 3
• Obtain complete blood count, electrolytes, renal function, and thyroid function to identify secondary causes 4

Management

First-Line Pharmacological Treatment

Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, or pregabalin) are strongly recommended as first-line therapy for post-traumatic RLS, with moderate certainty of evidence. 3

• Gabapentin: Start 300 mg three times daily; titrate by 300 mg/day every 3–7 days to maintenance dose of 1800–2400 mg/day divided TID; maximum 3600 mg/day 3
• Pregabalin: Allows twice-daily dosing with potentially superior bioavailability; start 50 mg TID or 75 mg BID, increase to 300 mg/day after 3–7 days, then by 150 mg every 3–7 days as tolerated; maximum 600 mg/day 3
• Gabapentin enacarbil: Prodrug formulation with improved pharmacokinetics 3

Iron Supplementation

• Oral ferrous sulfate 325 mg daily or every other day if ferritin ≤75 ng/mL or transferrin saturation <20% (conditional recommendation, moderate certainty) 3
• IV ferric carboxymaltose 750–1000 mg in one or two infusions for rapid correction, especially if oral iron fails or ferritin is 75–100 ng/mL (strong recommendation, moderate certainty) 3

Alternative Treatment: Dopamine Agonists

The case series of post-traumatic RLS in SCI patients used pramipexole with excellent outcomes 2:

• Initial dosing ranged from 0.09–0.72 mg/day 2
• All four patients reported sustained benefit at follow-up periods of 16–49 months 2
• RLS severity scores improved dramatically (e.g., 32→11,37→12,33→12) 2

However, current guidelines suggest against standard use of dopamine agonists due to 7–10% annual augmentation risk (paradoxical worsening with earlier onset, increased intensity, and spread to other body parts). 3

• Dopamine agonists may be considered only for short-term use in patients who prioritize immediate symptom relief over long-term adverse effects 3
• If augmentation develops, transition to alpha-2-delta ligands or opioids 3

Refractory Cases

• Extended-release oxycodone 5–10 mg at bedtime or other low-dose opioids (methadone 5–10 mg daily, buprenorphine) are conditionally recommended for moderate to severe refractory RLS (moderate certainty) 3
• Long-term studies show only modest dose escalation over 2–10 years with relatively low abuse risk in appropriately screened patients 3
• Screen for opioid-use-disorder risk and monitor for respiratory depression, especially if obstructive sleep apnea is present 3

Non-Pharmacological Options

• Bilateral high-frequency peroneal nerve stimulation is conditionally recommended as a non-invasive alternative (moderate certainty) 3

Medications to Avoid

• Strong recommendation against: Cabergoline (cardiac valvular fibrosis risk) 3
• Conditional recommendation against: Bupropion, carbamazepine, clonazepam, valproic acid, valerian 3
• Avoid in post-traumatic RLS: Levodopa (very high augmentation risk, conditional recommendation against standard use) 3

Addressing Exacerbating Factors

• Eliminate alcohol, caffeine, and nicotine, especially within 3 hours of bedtime 1, 3
• Review and discontinue (if possible) antihistaminergic medications, serotonergic medications, and antidopaminergic medications 3
• Treat untreated obstructive sleep apnea if present 3

Monitoring and Follow-Up

• Reassess RLS severity at 4–6 weeks after treatment initiation 3
• Repeat iron studies every 6–12 months, as brain iron deficiency may persist despite clinical improvement 3
• Monitor for augmentation if dopamine agonists are used: earlier symptom onset, increased intensity, spread to arms/trunk 3
• Evaluate both nighttime symptom relief and daytime functional outcomes (alertness, mood, quality of life) 3

Key Clinical Pearls for Post-Traumatic RLS

• In SCI patients with infralesional involuntary movements or dysesthesia that respond poorly to conventional antispastic or analgesic treatment, actively consider RLS or periodic limb movements as the diagnosis. 2
• Post-traumatic RLS appears eminently treatable when correctly diagnosed, with excellent long-term outcomes reported in the SCI case series 2
• The pathophysiology likely involves both the primary RLS mechanisms (dopamine transmission insufficiency, low iron storage) and spinal cord dysfunction from the trauma 5, 6, 2
• Symptoms can occur in both complete and incomplete SCI, and may affect upper extremities in addition to lower extremities 2